Document Detail

The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.
MedLine Citation:
PMID:  22998368     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The most common risk factors for heart failure are hypertension and myocardial infarction. Angiotensin receptor blockers (ARBs) attenuate the deleterious effects of angiotensin II. Valsartan is a once or twice daily ARB that is FDA-approved for hypertension, LV dysfunction post-myocardial infarction and congestive heart failure as both an adjunct in ACE-inhibitor tolerant, and alternative in ACE-I intolerant patients.
AREAS COVERED: This article presents a comprehensive review of the literature regarding the pharmacokinetics and pharmacodynamics of valsartan, with particular attention paid to the post-myocardial infarction population.
EXPERT OPINION: Valsartan is a safe, well-tolerated and readily titratable ARB. In addition to its vasodilatory effects there are pleotropic effects associated with the ARB such as modulation of a number of neurohormonal regulators, cytokines and small molecules. Given the clear evidence-based benefits above and beyond its hypertensive properties, it has the potential, if priced appropriately, to grow in its impact as a pharmacotherapeutic long after its patent expires.
Cassandra D Benge; James A S Muldowney
Related Documents :
8037518 - Changes in the antioxidative defensive system during open heart operations in humans.
23275278 - Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucind...
24636548 - Medical therapy versus implantable cardioverter -defibrillator in preventing sudden car...
25093738 - Pharmacogenomics in heart failure: where are we now and how can we reach clinical appli...
7191648 - Changes in mixed venous and coronary sinus p50 secondary to anesthesia and cardiac dise...
15172198 - Effects of ventricular unloading on apoptosis and atrophy of cardiac myocytes.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2012-09-24
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  8     ISSN:  1744-7607     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-17     Completed Date:  2013-03-28     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1469-82     Citation Subset:  IM    
Nashville Veterans Affairs Medical Center, Cardiology Section, 1310 24th Avenue South, Nashville, TN 37212-263, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / pharmacology
Angiotensin Receptor Antagonists / pharmacokinetics*,  pharmacology*
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Dose-Response Relationship, Drug
Drug Evaluation
Hypertension / drug therapy
Myocardial Infarction / drug therapy*,  physiopathology
Randomized Controlled Trials as Topic
Risk Factors
Tetrazoles / chemistry,  pharmacokinetics*,  pharmacology*
Valine / analogs & derivatives*,  chemistry,  pharmacokinetics,  pharmacology
Grant Support
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Tetrazoles; 11128-99-7/Angiotensin II; 137862-53-4/valsartan; 7004-03-7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ruthenium-Catalyzed Aldehyde Functionality Reshuffle: Selective Synthesis of E-2-Arylcinnamaldehydes...
Next Document:  Trifluoromethylation of ?-Haloketones.